Janssen Pharmaceuticals, Inc. is a U.S.-based pharmaceutical company within the Janssen Pharmaceutical Companies of Johnson & Johnson. Headquartered in Titusville, New Jersey, it researches, develops, manufactures, and markets prescription medicines. Its portfolio and R&D span multiple therapeutic areas, including oncology, immunology, neuroscience, infectious diseases, cardiovascular and metabolic diseases, and pulmonary hypertension.
With capabilities covering small‑molecule and biologic modalities, Janssen conducts process chemistry, formulation science, and clinical development, supported by global Good Manufacturing Practice (GMP) operations and quality systems. The company produces active pharmaceutical ingredients (APIs) and finished dosage forms, and applies advanced drug-delivery technologies. It collaborates with academic, biotech, and manufacturing partners across the supply chain to advance therapies from discovery through commercialization, operating at the intersection of the life sciences and chemical manufacturing sectors.
Erda-iDRS shows safety and efficacy in Phase 1 for intermediate-risk bladder cancer, with high complete response rates and ongoing Phase 2 and 3 studies.
